Thrombocytopenia After Aortic Valve Replacement With Freedom Solo Bioprosthesis: A Propensity Study
Thrombocytopenia After Aortic Valve Replacement With Freedom Solo Bioprosthesis: A Propensity Study
复制标题
DOI：
10.1016/j.athoracsur.2010.01.040
复制
发表时间：
2010-05-01
影响因子：
4.6
通讯作者：
Caus, Thierry
中科院分区：
文献类型：
--
作者：
Piccardo, Alessandro;Rusinaru, Dan;Caus, Thierry
背景使用Freedom Solo生物瓣膜置换主动脉瓣后术后血小板减少症的发生率尚不清楚。本倾向匹配研究旨在评价接受Freedom Solo生物假体的患者血小板减少症的发生率和临床影响。回顾性筛选了2006年至2008年期间在我们机构接受Freedom Solo或Carpentier-Edwards Perimount心包假体主动脉瓣置换术的患者。排除标准包括双瓣膜置换术、再次手术和活动性心内膜炎。206例患者被认为有资格进行这项分析。使用倾向评分，获得了36对匹配的植入Freedom Solo或Perimount生物瓣膜的患者。主要终点是术后血小板减少症的发生。次要终点是术后血栓栓塞或出血事件和30天死亡率。配型前，重度血小板减少症（
Background. The incidence of postoperative thrombocytopenia after aortic valve replacement with the Freedom Solo bioprosthesis remains unclear. This propensity-matched study was carried out to evaluate the incidence and clinical impact of thrombocytopenia in patients receiving the Freedom Solo bioprosthesis.Methods. Patients who underwent aortic valve replacement with a Freedom Solo or Carpentier-Edwards Perimount pericardial prosthesis at our institution between 2006 and 2008 were screened retrospectively. Exclusion criteria included double valve replacement, redo surgery, and active endocarditis. Two hundred six patients were considered eligible for this analysis. Using propensity scores 36 matched pairs of patients with a Freedom Solo or Perimount bioprosthesis were obtained. The primary end point was the occurrence of postoperative thrombocytopenia. Secondary end points were postoperative thromboembolic or hemorrhagic events and 30-day mortality.Results. Before matching, severe thrombocytopenia (